



EUROPEAN MEDICINES AGENCY  
SCIENCE MEDICINES HEALTH

19 October 2012  
EMA/667865/2012  
Press Office

## Start of community reviews

CHMP meeting of 15-18 October 2012

Name	INN	Type of procedure	Scope
Immunological differences of pandemic vaccines (review of hypothesis on Pandemrix and development of narcolepsy)	Pandemic Influenza Vaccine (H1n1) (Split Virion, Inactivated, Adjuvanted)	Article 5(3) of Regulation (EC) 726/2004	Procedure triggered by EMA asking to give an opinion on preliminary research results by the Finnish National Institute of Health and Welfare (THL) investigating differences in the immunological response triggered by different pandemic influenza vaccines as a potential root cause for the development of narcolepsy in persons vaccinated with Pandemrix.  <i>Note: the CHMP concluded the review during this meeting (see separate Press Release).</i>

7 Westferry Circus • Canary Wharf • London E14 4HB • United Kingdom

**Telephone** +44 (0)20 7418 8400 **Facsimile** +44 (0)20 7418 8416

**E-mail** [info@ema.europa.eu](mailto:info@ema.europa.eu) **Website** [www.ema.europa.eu](http://www.ema.europa.eu)

An agency of the European Union

